Clinical Trial

Effects of Astragalus Membranaceus on Muscle Function

Study acronym: AD ASTRA
Completed
View on ClinicalTrials.gov →
Summary
This study evaluated whether daily supplementation with Astragali radix extract (480 mg/day) for 10 weeks could attenuate training-induced impairments in muscle function, joint pain, and inflammatory markers in moderately active young adults undergoing a structured resistance training program. Participants were randomized in a double-blind, placebo-controlled design to receive either Astragali radix extract (ASTRA) or placebo (PLA) during 8 weeks of progressive resistance training followed by 2 weeks of intensified training. The primary outcome was maximal voluntary isometric torque (MVIT) of the knee extensors. Secondary outcomes included one-repetition maximum (1RM) strength, knee range of motion, muscle soreness (VAS), and circulating blood biomarkers of muscle damage and inflammation.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-20.
Trial Details
NCT Number NCT07552675
Lead Sponsor University of Pavia
Conditions Healthy Adult
Enrollment 24 participants
Start Date 2023-09-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-02-25 (estimated)
Updated on ClinicalTrials.gov 2026-04-30